MAPK3 and colorectal cancer: In colorectal cancer cells, cetuximab induces cell death in an ERK-dependent manner [47,48], and enhanced ERK1/2 activity is a possible mechanism of cetuximab resistance in head and neck squamous cell carcinoma and colorectal cancer cells [49,50].